M1 Macrophage‐Derived Small Extracellular Vesicles as Synergistic Nanotherapeutics: Harnessing Intrinsic Anticancer Activity and Drug Delivery Capacity
Journal of Extracellular Vesicles · 2026
DOI: 10.1002/jev2.70242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Gaeun Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Indiana, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Macrophages, Drug Delivery Systems, Breast Neoplasms. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Small extracellular vesicles (sEVs) have emerged as next‐generation multifunctional nanotherapeutics due to their parental‐cell traits and role in intercellular communication. Among them, immune cell–derived sEVs are uniquely positioned to couple innate immunomodulatory activities with therapeutic payload delivery, making them highly attractive for cancer therapy. In particular, M1 macrophage‐derived sEVs (M1‐sEVs) preserve the tumour‐suppressive functions of their parent cells, including tumour microenvironment (TME) reprogramming, immune activation, and inhibition of cancer progression. However, the mechanisms by which these activities are coordinated within the TME, and whether they act independently or synergistically, remain poorly understood. Clarifying these mechanisms is crucial for harnessing their intrinsic bioactivity in combination with their natural capacity as drug delivery nanocarriers to optimize therapeutic efficacy. Here, we demonstrate that M1‐sEVs exhibit intrinsic stability and circulation longevity via ‘do not eat me’ ligands, as well as tumour‐homing ability revealed by proteomic profiling, enabling efficient uptake and deep infiltration in breast cancer models. Functionally, M1‐sEVs deliver antiproliferative microRNAs that suppress tumour metabolism, growth, and progression by inhibiting self‐renewal, adhesion, migration, motility, and invasion. Importantly, by integrating this endogenous bioactivity with exogenous doxorubicin loading, we achieved synergistic efficacy: a 3‐fold reduction in IC 50 in vitro (0.46 µM vs. 1.45 µM for free drug) and 70.18% tumour growth inhibition in vivo. These findings highlight M1‐sEVs as dual‐action nanotherapeutics that combine innate immune‐regulatory and tumour‐inhibitory functions with efficient drug delivery, advancing their development as powerful platforms for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Indiana, USA.
- Harper Cancer Research Institute, University of Notre Dame, Notre Dame, Indiana, USA.
- Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA.
ORCID-Profile: Gaeun Kim, Hyunsu Jeon, Runyao Zhu, Yichun Wang
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- National Science Foundation
- National Institutes of Health
Zitieren
APA
Kim, G., Jeon, H., Chao, A., Johnston, J., Zhu, R., Khong, C., Liu, Y., Liang, M., Lu, X., & Wang, Y. (2026). M1 Macrophage‐Derived Small Extracellular Vesicles as Synergistic Nanotherapeutics: Harnessing Intrinsic Anticancer Activity and Drug Delivery Capacity. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70242
Vancouver
Kim G, Jeon H, Chao A, Johnston J, Zhu R, Khong C, et al. M1 Macrophage‐Derived Small Extracellular Vesicles as Synergistic Nanotherapeutics: Harnessing Intrinsic Anticancer Activity and Drug Delivery Capacity. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70242
BibTeX
@article{Kim2026,
author = {Kim, Gaeun and Jeon, Hyunsu and Chao, Adrian and Johnston, James and Zhu, Runyao and Khong, Courtney and Liu, Yichen and Liang, Minzhi and Lu, Xin and Wang, Yichun},
title = {M1 Macrophage‐Derived Small Extracellular Vesicles as Synergistic Nanotherapeutics: Harnessing Intrinsic Anticancer Activity and Drug Delivery Capacity},
journal = {Journal of Extracellular Vesicles},
year = {2026},
doi = {10.1002/jev2.70242}
}
EUVIMED